AU5339798A - Immediately disintegrable medicinal compositions - Google Patents

Immediately disintegrable medicinal compositions

Info

Publication number
AU5339798A
AU5339798A AU53397/98A AU5339798A AU5339798A AU 5339798 A AU5339798 A AU 5339798A AU 53397/98 A AU53397/98 A AU 53397/98A AU 5339798 A AU5339798 A AU 5339798A AU 5339798 A AU5339798 A AU 5339798A
Authority
AU
Australia
Prior art keywords
medicinal compositions
immediately disintegrable
disintegrable
immediately
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU53397/98A
Inventor
Atsushi Kajiyama
Hirokazu Takagi
Masahiro Yanagisawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of AU5339798A publication Critical patent/AU5339798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
AU53397/98A 1996-12-25 1997-12-24 Immediately disintegrable medicinal compositions Abandoned AU5339798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34476896 1996-12-25
JP8-344768 1996-12-25
PCT/JP1997/004788 WO1998029137A1 (en) 1996-12-25 1997-12-24 Immediately disintegrable medicinal compositions

Publications (1)

Publication Number Publication Date
AU5339798A true AU5339798A (en) 1998-07-31

Family

ID=18371833

Family Applications (1)

Application Number Title Priority Date Filing Date
AU53397/98A Abandoned AU5339798A (en) 1996-12-25 1997-12-24 Immediately disintegrable medicinal compositions

Country Status (14)

Country Link
US (4) US20020031547A1 (en)
EP (2) EP1008354B1 (en)
JP (1) JP3988193B2 (en)
KR (1) KR100534504B1 (en)
CN (1) CN1132635C (en)
AR (1) AR009438A1 (en)
AT (1) ATE397459T1 (en)
AU (1) AU5339798A (en)
CA (1) CA2272586C (en)
DE (1) DE69738755D1 (en)
ES (1) ES2307303T3 (en)
TW (1) TW486370B (en)
WO (1) WO1998029137A1 (en)
ZA (1) ZA9711508B (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
JP2000191518A (en) * 1998-10-19 2000-07-11 Eisai Co Ltd Intraoral quickly collapsible tablet having improved solubility
DE19931708A1 (en) 1999-07-08 2001-01-18 Bayer Ag Process for the preparation of rapidly disintegrating solid pharmaceutical preparations
AR028253A1 (en) 2000-03-16 2003-04-30 Pfizer Prod Inc INHIBITORS OF THE GLUCOGENO FOSFORILASA
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
AU2001295999A1 (en) * 2000-10-24 2002-05-06 Ajinomoto Co., Inc. Nateglinide-containing preparations
EP1275377B1 (en) * 2001-07-11 2003-06-18 Apr Applied Pharma Research S.A. Granulates containing liposoluble substances and process of preparation thereof
CA2474835A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CN101664411A (en) * 2003-11-14 2010-03-10 味之素株式会社 Solid dispersion or medicinal solid dispersion preparation of phenylalanine derivative
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1750677B1 (en) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20080031825A1 (en) * 2004-08-20 2008-02-07 Yisheng Chen Pharmaceutical Compositions Comprising Effervescent Agents And Fenofibrate
DE102005026755A1 (en) * 2005-06-09 2006-12-14 Basf Ag Production of solid solutions of sparingly soluble active ingredients by short-term overheating and rapid drying
KR101233235B1 (en) * 2005-08-26 2013-02-15 에스케이케미칼주식회사 Pharmaceutical composition of pranlukast solid-dispersion with improved early dissolution rate and the method of preparing the composition
JP5209966B2 (en) * 2005-09-01 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for producing pharmaceutical composition with improved disintegration
CA2629904C (en) * 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
KR101784001B1 (en) 2006-04-04 2017-10-23 케이지 액퀴지션 엘엘씨 Oral dosage forms including an antiplatelet agent and an acid inhibitor
JP2007308479A (en) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd Solid-dispersed substance preparation
WO2008064259A2 (en) * 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
EP2263671B1 (en) * 2008-04-02 2016-07-20 Astellas Pharma Inc. Amide derivative-containing pharmaceutical composition
DE102009013611A1 (en) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Solid retigabine in non-crystalline form
ES2873502T3 (en) 2009-03-27 2021-11-03 Bend Res Inc Spray drying process
US9125809B2 (en) * 2009-04-03 2015-09-08 Nichi-Iko Pharmaceutical Co., Ltd. Pectin-containing jelly formulation
CN101810563B (en) * 2009-09-25 2012-04-25 宋洪涛 Tacrolimus ophthalmic in-situ gel preparation and preparation method thereof
CN102666403A (en) * 2009-11-19 2012-09-12 日本曹达株式会社 Reduction treatment method for ballast water
TWI564008B (en) 2010-09-30 2017-01-01 鹽野義製藥股份有限公司 Formulation for solubility enhancement of poorly soluble drugs
US20140030346A1 (en) * 2010-12-27 2014-01-30 Masashi Konishi Disintegrable core particle for pharmaceutical preparation
WO2012144463A1 (en) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US20140024723A1 (en) * 2012-07-17 2014-01-23 Dow Global Technologies Llc Composition comprising an organic liquid diluent and a specific hydroxypropyl methylcellulose
SI3725778T1 (en) * 2012-09-11 2022-02-28 Medivation Prostate Therapeutics Llc Formulations of enzalutamide
BR112015009004A8 (en) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd amorphous form of quinoline derivative and method of production thereof
MX368099B (en) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds.
AU2015214502B2 (en) 2014-02-05 2019-06-06 Merck Sharp & Dohme Llc Tablet formulation for CGRP-active compounds
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
TW201613579A (en) 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
HRP20221047T1 (en) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
EP3212169B1 (en) 2014-10-31 2021-01-13 Bend Research, Inc. Process for forming active domains dispersed in a matrix
CN107427505A (en) 2015-02-25 2017-12-01 卫材R&D管理有限公司 For the method for the bitter taste for suppressing quinoline
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016175230A1 (en) * 2015-04-28 2016-11-03 アステラス製薬株式会社 Pharmaceutical composition for oral administration
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US20190209469A1 (en) 2016-08-20 2019-07-11 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
JP7458317B2 (en) * 2017-10-31 2024-03-29 サムヤン、ホールディングス、コーポレーション Oral solid preparation composition with improved disintegration and method for producing the same
WO2019172420A1 (en) * 2018-03-09 2019-09-12 協和発酵キリン株式会社 Pharmaceutical composition
WO2020027011A1 (en) * 2018-07-30 2020-02-06 中外製薬株式会社 Solid dispersion of hydantoin derivative
EP3972569A1 (en) 2019-05-23 2022-03-30 Helm AG Nanoparticles comprising enzalutamide
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4255413A (en) * 1979-10-01 1981-03-10 Smithkline Corporation Gelatin capsule dosage unit containing triamterene
JPS56110612A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
JPS5948810A (en) 1982-09-10 1984-03-21 Sony Corp Mask of data for magnetic recording body and reproducing method therefor
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
ES2043766T3 (en) * 1987-11-11 1994-01-01 Pharmascience Lab A NEW PHARMACEUTICAL COMPOSITION THAT INCLUDES EXIFONE AND A POLYMER SOLUBLE IN WATER.
US4964686A (en) * 1987-12-14 1990-10-23 Canon Kabushiki Kaishi Finder optical device
JP2814513B2 (en) 1988-02-03 1998-10-22 吉富製薬株式会社 Pharmaceutical composition with improved dissolution
US5091191A (en) * 1988-02-03 1992-02-25 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition with improved dissolution property
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
JP2906528B2 (en) * 1990-02-14 1999-06-21 大正製薬株式会社 Solid preparation for internal use with enhanced absorption
JP3240729B2 (en) * 1993-03-05 2001-12-25 株式会社リコー Facsimile machine
PL182011B1 (en) * 1993-08-26 2001-10-31 Yamanouchi Pharma Co Ltd Benzazepine derivative, pharmaceutic composition and intermediate compounds
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
JPH08127533A (en) * 1994-11-01 1996-05-21 Taisho Pharmaceut Co Ltd Composition for oral solid pharmaceutical preparation
WO1996019974A1 (en) * 1994-12-27 1996-07-04 Kanebo, Ltd. Sustained-release preparation
JPH08231403A (en) * 1995-02-27 1996-09-10 Yamanouchi Pharmaceut Co Ltd Stable aqueous solution containing arginine vasopressin antagonist
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US5964686A (en) * 1997-11-07 1999-10-12 Griffin Automation, Inc. Method for forming slotted and creased box blanks
US6632455B2 (en) * 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability

Also Published As

Publication number Publication date
US7189415B2 (en) 2007-03-13
CA2272586C (en) 2005-11-22
US20070014856A1 (en) 2007-01-18
CN1241946A (en) 2000-01-19
US20020031547A1 (en) 2002-03-14
CN1132635C (en) 2003-12-31
US20050095289A1 (en) 2005-05-05
CA2272586A1 (en) 1998-07-09
KR20000062327A (en) 2000-10-25
DE69738755D1 (en) 2008-07-17
KR100534504B1 (en) 2005-12-08
EP1759712A2 (en) 2007-03-07
EP1008354B1 (en) 2008-06-04
AR009438A1 (en) 2000-04-12
JP3988193B2 (en) 2007-10-10
US20030003146A1 (en) 2003-01-02
US6899899B2 (en) 2005-05-31
EP1008354A1 (en) 2000-06-14
TW486370B (en) 2002-05-11
ZA9711508B (en) 1998-06-24
ES2307303T3 (en) 2008-11-16
EP1008354A4 (en) 2006-02-01
ATE397459T1 (en) 2008-06-15
WO1998029137A1 (en) 1998-07-09

Similar Documents

Publication Publication Date Title
AU5339798A (en) Immediately disintegrable medicinal compositions
AU4762797A (en) Pharmaceutical compositions
AU4016095A (en) Oral compositions
AU5136998A (en) Medicinal composition
EG24118A (en) Pharmaceutical compositions
AU3650895A (en) Oral compositions
AUPN411195A0 (en) Medicinal composition
AU2372095A (en) Oral compositions
AU8107998A (en) Pharmaceutical compositions
AU3777897A (en) Pharmaceutical compositions
AU5317598A (en) Novel pharmaceutical compositions
GB9610359D0 (en) Pharmaceutical compositions
GB9622681D0 (en) Pharmaceutical compositions
AU2427895A (en) Oral compositions
AU3460897A (en) Medicinal compositions
GB9606429D0 (en) Pharmaceutical compositions
GB9613457D0 (en) Pharmaceutical compositions
AU4326197A (en) Pharmaceutical compositions
AUPN862596A0 (en) Pharmaceutical compositions
AU4457597A (en) Pharmaceutical compositions
GB2308812B (en) Antiseptic compositions
AU1427895A (en) Pharmaceutical compositions
AU1544195A (en) Pharmaceutical compositions
GB9610136D0 (en) Pharmaceutical compositions
AU2896897A (en) Oral pharmaceutical compositions